Evenamide Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Evenamide comprises 3 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Schizophrenia. Most recent publication: Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial., Neuropharmacology, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
    Anand R, Turolla A, Chinellato G, et al. · Neuropharmacology · 2025
    PubMed: PMID 39708914 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia
  2. Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
    Anand R, Turolla A, Chinellato G, et al. · Int J Neuropsychopharmacol · 2024
    PubMed: PMID 39661380 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia
  3. Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
    Anand R, Turolla A, Chinellato G, et al. · Int J Neuropsychopharmacol · 2023
    PubMed: PMID 37349110 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia

Publications by year

2023–2025: 3 publications.

2023
1
2024
1
2025
1

Publications by indication

Schizophrenia (3)

  • Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
    Neuropharmacology · 2025 · PMID 39708914 · NCT07184619
  • Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
    Int J Neuropsychopharmacol · 2024 · PMID 39661380 · NCT07184619
  • Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
    Int J Neuropsychopharmacol · 2023 · PMID 37349110 · NCT07184619

Publications by journal

  • Int J Neuropsychopharmacol2 papers
  • Neuropharmacology1 paper

All Evenamide publications (3)

2025 (1 paper)

  1. Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
    Anand R, Turolla A, Chinellato G, et al. · Neuropharmacology · 2025 · Background
    PubMed: PMID 39708914 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia

2024 (1 paper)

  1. Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
    Anand R, Turolla A, Chinellato G, et al. · Int J Neuropsychopharmacol · 2024 · Background
    PubMed: PMID 39661380 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia

2023 (1 paper)

  1. Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
    Anand R, Turolla A, Chinellato G, et al. · Int J Neuropsychopharmacol · 2023 · Background
    PubMed: PMID 37349110 · NCT07184619 (ENIGMA-TRS 2) · Schizophrenia

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 26 May 2026 18:18:01 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).